Leo Pharma AS - Strategic SWOT Analysis Review

July 2021 | 37 pages | ID: LA398DA85828EN
GlobalData

Abstracts

Leo Pharma AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

LEO Pharma AS (LEO Pharma), a subsidiary of LEO Foundation, is a drug manufacturing company. It discovers, develops, manufactures and commercializes medicines for skin diseases and thrombosis. Its product portfolio spans pharmaceuticals for the treatment of diseases such as eczema, psoriasis, skin infections, actinic keratosis, non-melanoma skin cancer and thrombosis. The company also manufactures and markets products for the treatment of bacterial infections, coagulation, cardiovascular, antibiotics, osteoporosis and renal problems. LEO Pharma markets its products worldwide. The company has presence in Europe, the Middle East, Africa, Asia, the Americas and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.

Leo Pharma AS Key Recent Developments

Dec 16,2020: LEO Pharma strengthens global leadership team with appointment of Jorg Moller as Executive Vice President, Global Research and Development
Aug 31,2020: LEO Pharma divests four medicines to Cheplapharm for $357m
Jun 30,2020: LEO Pharma strengthens global leadership team
May 26,2020: RCSI and LEO Pharma partner to investigate blood clotting in breast cancer patients

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Leo Pharma AS - Key Facts
Leo Pharma AS - Key Employees
Leo Pharma AS - Key Employee Biographies
Leo Pharma AS - Major Products and Services
Leo Pharma AS - History
Leo Pharma AS - Company Statement
Leo Pharma AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Leo Pharma AS - Business Description
Product Category: Acne/Rosacea
Overview
Performance
Product Category: Actinic Keratosis
Overview
Performance
Product Category: Eczema and Skin Infections
Overview
Performance
Product Category: Other
Overview
Performance
Product Category: Psoriasis
Overview
Performance
Product Category: Thrombosis
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: International
Performance
Geographical Segment: The US
Performance
R&D Overview
Leo Pharma AS - Corporate Strategy
Leo Pharma AS - SWOT Analysis
SWOT Analysis - Overview
Leo Pharma AS - Strengths
Leo Pharma AS - Weaknesses
Leo Pharma AS - Opportunities
Leo Pharma AS - Threats
Leo Pharma AS - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Leo Pharma AS, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Dec 16, 2020: LEO Pharma strengthens global leadership team with appointment of Jorg Moller as Executive Vice President, Global Research and Development
Aug 31, 2020: LEO Pharma divests four medicines to Cheplapharm for $357m
Jun 30, 2020: LEO Pharma strengthens global leadership team
May 26, 2020: RCSI and LEO Pharma partner to investigate blood clotting in breast cancer patients

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Leo Pharma AS, Key Facts
Leo Pharma AS, Key Employees
Leo Pharma AS, Key Employee Biographies
Leo Pharma AS, Major Products and Services
Leo Pharma AS, History
Leo Pharma AS, Subsidiaries
Leo Pharma AS, Key Competitors
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Leo Pharma AS, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021